We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-12.43%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$367M
AUM Growth
-$16.9M
Cap. Flow
+$54.7M
Cap. Flow %
14.9%
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
38
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$25.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$4.15M
4
ACET icon
Adicet Bio
ACET
+$3.02M
5
ALEC icon
Alector
ALEC
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.3M
2
LONA
LeonaBio Inc
LONA
+$2.17M
3
COGT icon
Cogent Biosciences
COGT
+$1.67M
4
IMCR icon
Immunocore
IMCR
+$1.61M
5
NTUS
Natus Medical Inc
NTUS
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 80.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
76
Sutro Biopharma
STRO
$416M
$441K 0.12%
8,470
– –
MASI
77
DELISTED
Masimo
MASI
$392K 0.11%
3,000
– –
CGEN icon
78
Compugen
CGEN
$217M
$380K 0.1%
205,202
+75,000
+58% +$162K
LVTX
79
DELISTED
LAVA Therapeutics
LVTX
$379K 0.1%
128,335
-10,997
-8% -$38.1K
INGN icon
80
Inogen
INGN
$177M
$363K 0.1%
15,000
– –
VIGL
81
DELISTED
Vigil Neuroscience
VIGL
$257K 0.07%
99,754
– –
PHAS
82
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$227K 0.06%
378,611
– –
MDGL icon
83
Madrigal Pharmaceuticals
MDGL
$11.9B
$222K 0.06%
3,100
– –
LCTX icon
84
Lineage Cell Therapeutics
LCTX
$284M
$221K 0.06%
140,000
– –
CNTB
85
Connect Biopharma Holdings
CNTB
$137M
$218K 0.06%
+250,000
New +$368K
ASLN
86
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$170K 0.05%
8,593
+2,500
+41% +$55.5K
ANNX icon
87
Annexon
ANNX
$881M
$154K 0.04%
40,796
+10,000
+32% +$30.6K
LRMR icon
88
Larimar Therapeutics
LRMR
$425M
$98K 0.03%
49,996
– –
LONA
89
LeonaBio Inc
LONA
$72.6M
– –
-16,098
Closed -$2.17M
COGT icon
90
Cogent Biosciences
COGT
$7.23B
– –
-223,554
Closed -$1.67M
IMCR icon
91
Immunocore
IMCR
$1.69B
– –
-53,878
Closed -$1.61M
PHVS icon
92
Pharvaris
PHVS
$2.34B
– –
-34,615
Closed -$628K
INFI
93
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-120,097
Closed -$137K
HARP
94
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-10,516
Closed -$523K
SRGA
95
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-19,324
Closed -$176K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, DAFNA Capital Management held 97 positions worth $367M, down 4.4% from $384M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $54.7M of net new capital in Q2 2022, opening 3 new positions and adding to 38 existing holdings. Its largest new stake was Keros Therapeutics: 39,000 shares worth $1.08M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Karuna Therapeutics, Inc. Common Stock, an estimated $2.3M trimmed.

  • DAFNA Capital Management's largest Q2 2022 buy was Keros Therapeutics: 39,000 shares worth $1.08M.
  • DAFNA Capital Management added most to State Street SPDR S&P Biotech ETF in Q2 2022, an estimated $25.8M increase.
  • DAFNA Capital Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $2.17M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $367M portfolio in Q2 2022.
  • DAFNA Capital Management opened 3 new positions and closed 7 in Q2 2022.
  • DAFNA Capital Management's portfolio value fell 4.4% quarter-over-quarter to $367M.

Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.